Introduction
The class I lipid kinase family of phosphatidylinositol 3 kinase (PI3K) catalytic subunits are divided into class IA (p110α, p110β, and p110δ) and class IB (p110γ), according to both structure and interaction with the p85 and p55 regulatory subunits (1).
In response to activation, PI3Ks phosphorylate the D3 position on membrane phosphatidylinositides to generate phosphatidylinositol 3,4,5-triphosphate (PIP3); PIP3 serves as an important secondary messenger by recruiting and activating proteins that contain a pleckstrin homology (PH) domain including AKT and 3'-phosphoinositidedependent kinase-1 (PDK1). Recruitment of PDK1 to the plasma membrane to phosphroylate AKT at residue threonine-308 (T308) and phosphorylation of AKT at the serine-473 (S473) residue by mTORC2 fully activate the AKT pathway (2) . AKT activation is critical in the regulation of various cellular processes including cell growth, proliferation, survival, and metabolism (2, 3) , and aberrant PI3K/AKT signaling occurs commonly in cancer (4) (5) (6) . Gene mutation, amplification, and copy number gains of p110α have been shown in a variety of human cancers such as breast, endometrial, colon, lung and many others (5) (6) (7) . Cancer specific mutations have not frequently been found in the other isoforms.
Another PI3K/AKT activation pathway is through the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN); PTEN dephosphorylates 3-phosphoinositides and is frequently mutated, deleted, or downregulated in many human cancers leading to elevated PIP3 levels and further resulting in constitutive activation of the PI3K/AKT pathway (8) Author Manuscript Published OnlineFirst on November 15, 2013; DOI: 10.1158/1078-0432.CCR- and prostate tumor cells (9, 10) . However, tumor suppressor functions of PTEN have been expanded and include mechanisms that are PI3K/AKT independent (11). These functions include regulation of SRC through its protein phosphatase activity (12) , a crucial role in p53-mediated cellular senescence (13) , and the participation of nuclear PTEN in controlling genomic stability and cell cycle progression independent of phosphatase activity (14, 15) . Furthermore, it has not been well investigated whether PTEN loss would specifically function through the PI3K/AKT pathway to regulate tumor progression in various subsets of tumor types.
Several inhibitors targeting the PI3K pathway have been developed in preclinical discovery programs or clinical trials (16) (17) (18) (19) (20) , however, there has not yet been a small molecular weight inhibitor of the PI3K pathway that is approved for cancer treatment.
Inhibitors in this pathway often have inhibitory activity against both PI3Ks and mTOR kinases, potentially leading to greater combined toxicity than either target alone. The mTORC1 and mTORC2 complexes control critical pathways regulating cell proliferation, apoptosis, angiogenesis, and metabolism through AKT-dependent and AKT-independent mechanisms (16) (17) (18) (19) . Therefore, PI3K inhibitors that also inhibit mTOR kinase activities may carry extra toxicity through the disruption of mTOR function in normal cells. To develop a drug selectively targeting PI3K, we have screened compounds and identified PF-4989216 as a novel potent and selective PI3K inhibitor, as previously reported (20) .
Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of lung cancer worldwide (21) . SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases than other 6 with only 5% of patients surviving five years. Response to second-line chemotherapy for patients with refractory disease is less than 10%, and survival is three to four months (22, 23) . Multiple phase III trials have been conducted, however the survival of SCLC patients has not improved significantly over the years (24, 25) . Therefore, a targeted therapeutic approach is in strong demand for SCLC patients. In this study, we characterized a selective PI3K inhibitor in preclinical SCLC models to investigate whether selectively targeting the PI3K pathway may be a potential effective therapy in SCLC.
In this study, we have described the in vitro and in vivo anti-tumor activity of PF-4989216 in a panel of human small cell lung cancer cells (SCLCs). PF-4989216 inhibited the phsophorylation of PI3K downstream molecules and subsequently led to apoptosis induction and inhibition in cell proliferation, transformation, and xenograft tumor growth in SCLCs harboring a PIK3CA mutation. However, in SCLCs with PTEN loss, PF-4989216 inhibited PI3K signaling but did not induce BIM-mediated apoptosis and was not able to inhibit cell proliferation and transformation implicating different tumorigenesis and apoptosis mechanisms between PIK3CA mutation and PTEN loss in SCLCs. In conclusion, our results suggest that PF-4989216 is a potential cancer drug candidate for small cell lung cancer patients with PIK3CA mutation but not PTEN loss.
Materials and Methods

Selective PI3K inhibitor
Research. PF-4989216 was synthesized as previously described (20) . Compounds were dissolved in DMSO for the in vitro cellular assays. PF-4989216 was formulated in 0.5% methyl-cellulose as a suspension (v/v) for in vivo animal studies.
Cell culture, adenovirus infection, cell viability, anchorage independent growth, and
ELISA assays
Small-cell lung cancer cell lines NCI-H69, NCI-H1048, NCI-H1436, NCI-H82, NCI-H254, NCI-H526, NCI-H1963, NCI-H146, and NCI-H841 were obtained from American Type Culture Collection. Lu99A, Lu134B, and Lu134A were obtained from Difco Noble agar containing growth medium. Cultures were maintained for a minimum of four weeks by weekly addition of compound in fresh agar (0.35%) containing medium.
Microscope images of colony morphology were taken prior to colony visualization by addition of iodonitrotetrazolium chloride (1 mg/ml, Sigma-Aldrich, St Louis, MO, USA) for 18 hours. Colonies were counted using the colony count function on the Fluorchem Q Gel Imaging System (Alpha Innotech/Protein Simple). All assays were run in duplicate, and have been repeated at least twice.
Cells (25, ,000 cells/well) were seeded in a 96-well microtiter plate and cultured overnight. The next day, PF-4989216 was added to each well starting at 10 μM with a three-fold serial dilution for two hours. Cells were washed with PBS twice, and cell lysates were prepared and analyzed by pAKT S473 ELISAs following the manufacturer's instructions (Cell Signaling Technology Inc, Danvers, MA, USA).
The Rat/Mouse Insulin ELISA kit (Cat. # EZRMI-13K, EMD Millipore, St.
Charles, MO, USA) was used for the non-radioactive quantification of insulin in mouse serum samples according to the manufacture's instruction.
Glucose was measured on the ADVIA® 1200 System chemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA) according to the manufacturer's instructions using the Siemens ADVIA® 1200 Glucose Hexokinase reagent.
Immunoblotting and FACS
Cells and tumors were homogenized in lysis buffer (50 mM Tris-HCl, 1% NP-40, 0.5% TX-100, 150 mM NaCl, 1 mM Na 3 VO 4 , 1 mM NaF, and protease inhibitor cocktail). Protein concentration was determined using the BCA Protein Assay Kit pan-PI3K isoforms and demonstrated excellent selectivity when screened against more than 100 kinases and 50 non-kinases (20) . The selectivity profile of PF-4989216 is provided in Supplementary Table SI (Fig. 1B) .
There was no significant observation of cell cycle profile changes in the Lu134A cells treated with any concentration of PF-4989216 (Fig. 1B) . Therefore, the cell cycle results indicate that PF-4989216 blocked cell cycle progression and induced an increased sub-G1 cell population in both NCI-H69 and NCI-H1048 cell lines which harbor PI3CA mutation but not in Lu134B and Lu134A cell lines which exhibit functional loss of PTEN.
Next we investigated whether inhibition of PI3K activity by PF-4989216 was able to block cellular transformation of SCLCs. NCI-H69, NCI-H1048, Lu134B and Lu134A
Research. (Fig. 2C and 2D ).
These results suggest that inhibition of cell proliferation by PF-4989216 in PI3KCA mutant SCLC cells is likely due to inhibition in PI3K signaling, however the inhibition of PI3K activity in PTEN loss SCLC cells is not sufficient to block cell proliferation.
PF-4989216 induced BIM-mediated apoptosis in SCLCs with PIK3CA mutation
Since we observed sub-G1 changes in NCI-H69 and NCI-H1048 cells treated with PF-4989216, we next performed an extensive profiling of apoptosis markers after PF-4989216 treatment in these four cell lines. Similar to the cell cycle profiling results, PF-4989216 induced a considerable amount of cleaved PARP in NCI-H69 and NCI-H1048 cells (Fig. 3A and 3B ), but the high concentration of PF-4989216 treatment only moderately induced cleaved PARP in Lu134B cells (Fig. 3C) and not at all in Lu134A cells (Fig. 3D) . Next Bcl-2 family apoptosis markers were evaluated, and we found that BIM was the most noteworthy marker upon PF-4989216 treatments in NCI-H69 and NCI-H1048 cells in comparison to Lu134B and Lu134A cells. PF-4989216 treatment in NCI-H69 and NCI-H1048 cells induced increased levels of BIM-L and BIM-S; the latter is the shortest splicing form of the BIM protein and is more cytotoxic than the BIM-EL and BIM-L forms (30) . BIM-L and BIM-S are pre-existing in non-treated NCI-H69 and NCI-H1048 cells and after PF-4989216 treatment, the levels of both BIM-L and BIM-S were induced to a much higher level (Fig. 3A and 3B ). In contrast, while BIM-EL was 
further increase of either BIM-L or BIM-S in these lines (Fig. 3C and 3D) . These results clearly suggest that PF-4989216 was able to induce the more apoptotic BIM-S in NCI-H69 and NCI-H1048 cells which harbor PIK3CA mutation but not in Lu134B and Lu134A cells which harbor PTEN loss. A variety of cytotoxic agents were also used to investigate the production of BIM isoforms in these four cell lines, and results indicates that both BIM-L and BIM-S can be induced by various cytotoxic agents in these four cell lines, although BIM-S induction is relatively more limited to NCI-H1048 and NCI-H69, suggesting that PTEN loss could protect cells from BIM-S mediated apoptosis ( Supplementary Fig. S6 ). These results also imply that a differential mechanism between PIK3CA mutant versus PTEN loss SLCLs may be driven by BIM-mediated apoptosis.
Furthermore, we observed a decrease in pBAD by PF-4989216 in NCI-H1048 cells but the decreased level of pBAD was not very pronounced in the other three cell lines, which may suggest that the pBAD decrease in NCI-H1048 cells may be cell line specific and may help explain why these cells are the most sensitive to PF-4989216 treatment. As autophagy has been implicated in SCLCs via the PI3K/mTOR pathway (31, 32), we also examined autophagy markers in cells treated with PF-4989216. We observed the conversion of LC3-I to LC3-II in NCI-H1048 and NCI-H69 but not in Lu134B or Lu134A cells (Fig. 3) , suggesting that autophagy induction may be also playing a role in anti-tumor activity by PI3K inhibition in these SCLC lines.
PF-4989216 inhibited tumor growth of SCLCs in mice
Since PF-4989216 was able to block cellular transformation of NCI-H69 and NCI-H1048 cells, we next performed studies to determine the in vivo activity of PF-4989216 in these two SCLC models. First, PF-4989216 was administered orally once to PI3K signaling is required for insulin-induced increases in glucose transport via the insulin receptor activation of PI3K and AKT to regulate GLUT4 trafficking (33, 34) .
Inhibitors of the PI3K/mTOR/AKT pathway have been shown to elevate serum glucose and insulin levels (35, 36); therefore, the serum glucose and insulin levels in mice treated with PF-4989216 were also measured (Fig. 4B) . At 350 mg/Kg, PF-4989216 only induced moderate increases of serum insulin or glucose and the levels of both insulin and glucose returned to basal levels after the four hour time point. Therefore, these results suggest that PF-4989216 may have a better therapeutic window in terms of a potential insulin resistance mechanism in comparison to PI3K/mTOR dual inhibitors which do induce higher serum insulin (36). SCID mice bearing NCI-H69 or NCI-H1048 xenograft tumors were dosed once with PF-4989216 (350 mg/Kg) and tumors were collected and processed to perform western blot analysis to determine the inhibitory activity of PF-4989216 at various time points against phosphorylation of AKT and the downstream molecule S6RP (Fig. 5A and   6A ). Similarly, SCID mice bearing NCI-H69 or NCI-H1048 tumors were also dosed S7 ). In the NCI-H69 model, dose-dependent tumor growth inhibition (TGI) was observed with PF-4989216, and at 350 mg/Kg induced 99.9 % TGI (Fig. 5C ). The mice in the 350mg/Kg group received long term dosing in order to evaluate whether tumors would become resistant. PF-4989216 (350 mg/Kg) was able to maintain tumor stasis for more than 2 months before tumor volumes began to increase, presumably because the xenografts became resistant to PF-4989216 treatment (Fig. 5D ). In the NCI-H1048 (Fig. 6C) . The NCI-H1048 model is also more sensitive to PF-4989216 in vitro as seen in cellular assays, possibly due to the double mutations in PIK3CA that might lead these cells to be more addicted to PI3K activation for cell growth and transformation. Two PTEN loss SCLC models, Lu134A and NCI-H1436, were also tested in TGI studies with PF-4989216, and not surprisingly, PF-4989216 did not induce significant tumor growth inhibition in either models ( Supplementary Fig. S8 ). The in vivo results indicate a good correlation between in vitro and in vivo efficacy, and further confirm that PF-4989216 is an effective drug candidate capable of inducing anti-tumor activity in mice bearing human SCLC tumors with PIK3CA mutation.
Discussion
Novel targeted therapies are urgently demanded in small cell lung cancer (SCLC) patients due to the very unsatisfactory survival rate in this patient population. Mutations in PIK3CA and PTEN occur frequently in the SCLC patient population (Table I) 
the detailed molecular mechanism still needs to be investigated further to fully understand the differences between PIK3CA mutation versus PTEN loss in the process of tumorigenesis in SCLCs, our study provides the preclinical evidence suggesting that it is preferred to select SCLC patients with PIK3CA mutation for the clinical development of PF-4989216 or other PI3K inhibitors.
Most of the inhibitors targeting the PI3K pathway have inhibitory activity against both PI3Ks and mTOR kinases, and several of these inhibitors are now in the clinical trial phase (19, 36, 40) . However, none of these agents has a trial in a SCLC PI3K mutant selected patient population. Since mTOR kinases control multiple tumor-related pathways through AKT dependent and AKT independent mechanisms (16) (17) (18) (19) 
In conclusion, we have developed a selective PI3K inhibitor, PF-4989216, which potently inhibits PI3K signaling as well as in vitro and in vivo tumor progression in SCLC lines with a PIK3CA mutation. Our results also reveal there may be different molecular mechanisms that are likely modulated by BIM-mediated apoptosis between PIK3CA mutation and PTEN loss that regulate tumor progression in SCLCs.
Furthermore, our preclinical data provide insight for clinical development of PF-4989216 in SCLC patients that harbor a PIK3CA mutation. were treated with PF-4989216 (10, 100, 1000, and 10000 nM) for 2, 6, or 24 hours. Cell lysates were prepared and subject to SDS-PAGE, and western analysis was performed with the indicated antibodies. GAPDH was included as a protein loading control. 
